2026-06-17T21:40:56Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/57032021-11-02T12:01:28Zcom_10259_3924com_10259_5086com_10259_2604col_10259_3925

Martínez García, David Manero Rupérez, Noemí Quesada Pato, Roberto Korrodi Gregório, Luís Soto Cerrato, Vanessa 2021-04-13T10:30:17Z 2021-04-13T10:30:17Z 2019-05 0198-6325 http://hdl.handle.net/10259/5703 10.1002/med.21547 1098-1128 Survivin is a small protein that belongs to the inhibitor of apoptosis protein family. It is abundantly expressed in tumors compared with adult differentiated tissues, being associated with poor prognosis in many human neoplasms. This apoptotic inhibitor has a relevant role in both the promotion of cancer cell survival and in the inhibition of cell death. Consequently, aberrant survivin expression stimulates tumor progression and confers resistance to several therapeutic strategies in a variety of tumors. In fact, efficient survivin downregulation or inhibition results in spontaneous apoptosis or sensitization to chemotherapy and radiotherapy. Therefore, all these features make survivin an attractive therapeutic target to treat cancer. Currently, there are several survivin inhibitors under clinical evaluation, although more specific and efficient survivin inhibitors are being developed. Moreover, novel combination regimens targeting survivin together with other therapeutic approaches are currently being designed and assessed. In this review, recent progress in the therapeutic options targeting survivin for cancer treatment is analyzed. Direct survivin inhibitors and their current development status are explored. Besides, the major signaling pathways implicated in survivin regulation are described and different therapeutic approaches involving survivin indirect inhibition are evaluated. Finally, promising novel inhibitors under preclinical or clinical evaluation as well as challenges of developing survivin inhibitors as a new therapy for cancer treatment are discussed. Consejería de Educación, Junta de Castilla y León. Grant Number: BU092U16 Instituto de Salud Carlos III. Grant Number: FIS PI18/00441 application/pdf eng Wiley Medicinal Research Reviews. 2019, V. 39, n. 3, p. 887-909 https://doi.org/10.1002/med.21547 info:eu-repo/grantAgreement/JCyL/BU092U16 anticancer therapy apoptosis chemoresistance inhibitor ofapoptosis proteins SMAC mimetics survivin inhibitors Química orgánica Chemistry, Organic Therapeutic strategies involving survivin inhibition in cancer info:eu-repo/semantics/article info:eu-repo/semantics/submittedVersion info:eu-repo/semantics/openAccess Medicinal Research Reviews 39 3 887 909